The North America Sickle Cell Disease Treatment Market would witness market growth of 27.0% CAGR during the forecast period (2023-2030).
Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by a genetic mutation affecting hemoglobin, which transports oxygen and is found in red blood cells. The disease impacts red blood cells with sickle shapes, resulting in defective hemoglobin and improper blood flow. The most prevalent symptoms of sickle cell disease are shortness of breath and fatigue.
According to the Centres for Disease Control and Prevention (CDC), the estimated number of SCD sufferers in the United States is 100,000. The industry is anticipated to be driven by rising immigration, improved healthcare services, and a sizable population of African heritage.
The main medications authorized for treating SCD by the US FDA are hydroxyurea and Endari as of 2018. Additionally, the forthcoming commercialization of medications, including voxelotor, CTX001, and Mitapivat, is anticipated to fuel market expansion. Blood transfusions, antibiotics to cure infections, and drugs to ease symptoms brought on by complications of sickle cell anemia are the usual treatments healthcare providers use to treat sickle cell anemia.
In North America, homozygous HbS disease, an autosomal recessive illness, is the most prevalent kind of SCD. Vaso-occlusive crises happen in about half of people with homozygous HbS illness. The occurrence of crises can occur at any time. Some people experience up to six episodes a year, but others may only experience them rarely or never. The frequency of crises normally follows a predictable pattern for each person. Both the United States and Canada have diverse populations, and SCD disproportionately affects certain ethnic groups, such as those of African, Mediterranean, Middle Eastern, and South Asian descent. As these populations continue to grow, the demand for tailored treatments and specialized healthcare services for SCD will also increase.
The US market dominated the North America Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,908.1 Million by 2030. The Canada market is experiencing a CAGR of 29.9% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 28.8% during (2023 - 2030).
Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Sickle Cell Disease Treatment Market is Projected to reach USD 7.3 Billion by 2030, at a CAGR of 27.9%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Treatment
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
By End-Use
- Hospitals
- Specialty Clinics
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer Inc.
- bluebird bio, Inc.
- CSL Limited
- Emmaus Life Sciences, Inc.
- Bristol Myers Squibb Company
- CRISPR Therapeutics AG
- Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
- Novo Nordisk A/S
- Medunik USA (Duchesnay Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Sickle Cell Disease Treatment Market, by Treatment
1.4.2 North America Sickle Cell Disease Treatment Market, by End-Use
1.4.3 North America Sickle Cell Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. North America Sickle Cell Disease Treatment Market by Treatment
5.1 North America Blood Transfusion Market by Country
5.2 North America Pharmacotherapy Market by Country
5.3 North America Bone Marrow Transplant Market by Country
Chapter 6. North America Sickle Cell Disease Treatment Market by End-use
6.1 North America Hospitals Market by Country
6.2 North America Specialty Clinics Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Sickle Cell Disease Treatment Market by Country
7.1 US Sickle Cell Disease Treatment Market
7.1.1 US Sickle Cell Disease Treatment Market by Treatment
7.1.2 US Sickle Cell Disease Treatment Market by End-use
7.2 Canada Sickle Cell Disease Treatment Market
7.2.1 Canada Sickle Cell Disease Treatment Market by Treatment
7.2.2 Canada Sickle Cell Disease Treatment Market by End-use
7.3 Mexico Sickle Cell Disease Treatment Market
7.3.1 Mexico Sickle Cell Disease Treatment Market by Treatment
7.3.2 Mexico Sickle Cell Disease Treatment Market by End-use
7.4 Rest of North America Sickle Cell Disease Treatment Market
7.4.1 Rest of North America Sickle Cell Disease Treatment Market by Treatment
7.4.2 Rest of North America Sickle Cell Disease Treatment Market by End-use
Chapter 8. Company Profiles
8.1 bluebird bio, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.3.4 Recent strategies and developments:
8.3.4.1 Trials and Approvals:
8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
8.4.1 Company Overview
8.4.2 Recent strategies and developments:
8.4.2.1 Trials and Approvals:
8.4.3 SWOT Analysis
8.5 CSL Limited
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental & Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Trials and Approvals:
8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Product Launches and Product Expansions:
8.10.4.3 Trials and Approvals:
8.10.5 SWOT Analysis
TABLE 1 North America Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 2 North America Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Sickle Cell Disease Treatment Market
TABLE 4 Product Launches And Product Expansions– Sickle Cell Disease Treatment Market
TABLE 5 Acquisition and Mergers– Sickle Cell Disease Treatment Market
TABLE 6 Trials and Approvals- SICKLE Cell Disease Treatment Market
TABLE 7 North America Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 8 North America Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 9 North America Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 13 North America Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 16 North America Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 17 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 25 US Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 26 US Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 27 US Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 28 US Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 29 US Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 US Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 Canada Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 32 Canada Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 33 Canada Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 34 Canada Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 35 Canada Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 Canada Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 Mexico Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 38 Mexico Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 39 Mexico Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 40 Mexico Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 41 Mexico Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 42 Mexico Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 43 Rest of North America Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 44 Rest of North America Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 45 Rest of North America Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 46 Rest of North America Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 47 Rest of North America Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 48 Rest of North America Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 49 Key Information – bluebird bio, Inc.
TABLE 50 Key Information – CRISPR Therapeutics AG
TABLE 51 Key Information – Agios Pharmaceuticals, Inc.
TABLE 52 Key Information – Medunik USA
TABLE 53 Key Information – CSL Limited
TABLE 54 Key Information – Novo Nordisk A/S
TABLE 55 Key Information – Novartis AG
TABLE 56 Key Information – Pfizer, Inc.
TABLE 57 Key Information – Bristol Myers Squibb Company
TABLE 58 Key Information – Emmaus Life Sciences, INC.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Sickle Cell Disease Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Sickle Cell Disease Treatment Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Sickle Cell Disease Treatment Market
FIG 8 North America Sickle Cell Disease Treatment Market share by Treatment, 2022
FIG 9 North America Sickle Cell Disease Treatment Market shar by Treatment, 2030
FIG 10 North America Sickle Cell Disease Treatment Market by Treatment, 2019 - 2030, USD Million
FIG 11 North America Sickle Cell Disease Treatment Market share by End-use, 2022
FIG 12 North America Sickle Cell Disease Treatment Market shar by End-use, 2030
FIG 13 North America Sickle Cell Disease Treatment Market by End-use, 2019 - 2030, USD Million
FIG 14 North America Sickle Cell Disease Treatment Market share by Country, 2022
FIG 15 North America Sickle Cell Disease Treatment Market share by Country, 2030
FIG 16 North America Sickle Cell Disease Treatment Market by COuntry, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: bluebird bio, Inc.
FIG 18 SWOT Analysis: CRISPR Therapeutics AG
FIG 19 SWOT Analysis: Agios Pharmaceuticals, Inc.
FIG 20 SWOT Analysis: Medunik USA
FIG 21 SWOT Analysis: CSL Limited
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 Recent strategies and developments: Novartis AG
FIG 24 SWOT Analysis: Novartis AG
FIG 25 SWOT Analysis: Pfizer, Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company
FIG 27 Recent strategies and developments: Emmaus Life Sciences, Inc.
FIG 28 SWOT Analysis: Emmaus Life Sciences, Inc.